A 70-year-old client receiving clopidogrel 75 mg orally daily after a recent percutaneous coronary intervention develops gastroesophageal reflux symptoms. The provider considers adding a proton pump inhibitor for GI protection. Which intervention by the nurse is most appropriate?
1Administer omeprazole 20 mg orally once daily as prescribed, and reassure the client that this proton pump inhibitor will effectively manage reflux without compromising the antiplatelet benefit of clopidogrel following percutaneous coronary intervention.
2Contact the provider to request an increase in the clopidogrel dose to 150 mg orally daily, stating that this higher dose will compensate for any reduction in clopidogrel activation caused by concurrent omeprazole therapy after percutaneous coronary intervention.
3Notify the provider that omeprazole and esomeprazole are strong CYP2C19 inhibitors that reduce clopidogrel activation and may decrease antiplatelet effect, and ask whether pantoprazole (a weaker CYP2C19 inhibitor) or an H2 blocker such as famotidine could be substituted.✓ Correct answer
4Temporarily discontinue clopidogrel for 48 hours to determine if the reflux symptoms improve, as these symptoms could be a side effect of the antiplatelet medication rather than a need for acid suppression therapy in a patient with recent percutaneous coronary intervention.
Explanation
Clopidogrel + PPI — CYP2C19 interaction Clopidogrel is a P2Y12 receptor antagonist prodrug activated mainly by CYP2C19. Omeprazole and esomeprazole are strong CYP2C19 inhibitors and reduce activation of clopidogrel, lowering antiplatelet effect — observational data suggest possible increase in CV events; FDA carries a labeling warning.
Preferred PPIs when GI prophylaxis is needed: • Pantoprazole (Protonix) — weaker CYP2C19 inhibitor, generally considered the safer PPI partner for clopidogrel. • Lansoprazole, dexlansoprazole — intermediate. • H2 blocker famotidine is a reasonable alternative without the CYP2C19 issue (cimetidine is NOT preferred because it inhibits multiple CYP enzymes).
Other key clopidogrel teaching: • Genetic CYP2C19 poor metabolizers have reduced response — alternative P2Y12 (prasugrel, ticagrelor) considered. • Hold typically 5-7 days before elective surgery; do not stop without provider plan after stent. • Bleeding precautions; avoid herbal antiplatelet products. • Reversal: no specific antidote; for life-threatening bleed give platelets and supportive care.
In-depth explanation
Clinical reasoning summary Clopidogrel + PPI — CYP2C19 interaction Clopidogrel is a P2Y12 receptor antagonist prodrug activated mainly by CYP2C19. Omeprazole and esomeprazole are strong CYP2C19 inhibitors and reduce activation of clopidogrel, lowering antiplatelet effect — observational data suggest possible increase in CV events; FDA carries a labeling warning.
Preferred PPIs when GI prophylaxis is needed: • Pantoprazole (Protonix) — weaker CYP2C19 inhibitor, generally considered the safer PPI partner for clopidogrel. • Lansoprazole, dexlansoprazole — intermediate. • H2 blocker famotidine is a reasonable alternative without the CYP2C19 issue (cimetidine is NOT preferred because it inhibits multiple CYP enzymes).
Other key clopidogrel teaching: • Genetic CYP2C19 poor metabolizers have reduced response — alternative P2Y12 (prasugrel, ticagrelor) considered. • Hold typically 5-7 days before elective surgery; do not stop without provider plan after stent. • Bleeding precautions; avoid herbal antiplatelet products. • Reversal: no specific antidote; for life-threatening bleed give platelets and supportive care.